- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Trial completion date, Trial primary completion date: A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (clinicaltrials.gov) - May 17, 2022 P3, N=550, Recruiting, In this real-world study, fremanezumab demonstrated effectiveness for migraine regardless of migraine type or the presence of factors contributing to DTT migraine (MO, GAD, MDD, or prior exposure to a different CGRP mAb). Trial completion date: Nov 2027 --> Apr 2027 | Trial primary completion date: Jul 2027 --> Dec 2026
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Journal, Real-world evidence: A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. (Pubmed Central) - May 12, 2022 Overall, adherence and persistence to fremanezumab in this real-world study was high in patients with migraine, with higher rates observed for quarterly fremanezumab. Patients who were persistent for ≥ 6 months experienced significant reductions in acute and preventive migraine medication use, while a subgroup of migraine patients with comorbid depression and anxiety at baseline showed significant reductions in antidepressant and anxiolytic medication use.
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Trial completion date, Trial primary completion date: A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents (clinicaltrials.gov) - May 11, 2022 P3, N=550, Recruiting, Patients who were persistent for ≥ 6 months experienced significant reductions in acute and preventive migraine medication use, while a subgroup of migraine patients with comorbid depression and anxiety at baseline showed significant reductions in antidepressant and anxiolytic medication use. Trial completion date: Dec 2024 --> Nov 2027 | Trial primary completion date: Aug 2024 --> Jul 2027
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Trial completion date, Trial primary completion date: Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden (clinicaltrials.gov) - Apr 13, 2022 P4, N=40, Completed, This real-world study demonstrated effectiveness of fremanezumab treatment for up to 6 months, irrespective of dosing regimen or number of prior migraine preventive treatment failures, reflecting ongoing, clinically meaningful improvements in patient outcomes. Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: CGRP-1: CGRP Inhibition, Autonomic Function, and Migraine (clinicaltrials.gov) - Apr 11, 2022 P=N/A, N=120, Recruiting, Younger age emerges as a potential response predictor. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. (Pubmed Central) - Apr 8, 2022 Our findings suggest extending the efficacy treatment evaluation for antiCGRP mAbs to 6 months, also in terms of reimbursement policies. The cessation of CGRP(-receptor) antibodies migraine prophylaxis was associated with a significant increase of migraine frequency and acute medication intake over time.
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Enrollment open: Fremanezumab, Migraine and Sleep (clinicaltrials.gov) - Mar 31, 2022 P4, N=100, Recruiting, However, because there are several limitations, the findings of the current NMA should be taken into consideration with caution. Not yet recruiting --> Recruiting
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Qulipta (atogepant) / AbbVie
Understanding sites of action in #migraine #treatment: #atogepant an oral #CGRP antagonist, partially inhibits both Aδ and C-fibers in contrast to #fremanezumab, a CGRP-targeted antibody, which only inhibits Aδ fibers, and onabotulinumtoxinA which inhibits C-fibers (Twitter) - Mar 26, 2022
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva
Real-World Reductions in Acute Medication Use for Patients with Migraine Initiating Fremanezumab: A 12-Month Retrospective US Claims Analysis (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1365; Significant reductions were also seen in mean (SD) annual numbers of total claims for migraine-related acute medication prescriptions (10.6 [10.7] to 9.3 [10.5]), triptans (4.9 [6.4] to 4.0 [5.7]), NSAIDs (2.0 [3.3] to 1.9 [3.4]), and opioids (2.6 [5.9] to 2.5 [5.7]; all P <0.05), except for ergots (0.1 [0.7] to 0.1 [0.9]; P =0.3713). CONCLUSION Fremanezumab treatment was associated with statistically significant reductions in acute medication use from 12 months pre-index to 12 months post-index.
|